Watch List for Traders: Synacor (NASDAQ:SYNC), International Paper Company (NYSE:IP), Aerie Pharmaceuticals (NASDAQ:AERI), Asta Funding (NASDAQ:ASFI)

Clovis Oncology, Inc. (NASDAQ:CLVS) shares increased 0.89% in last trading session and ended the day at $19.37. CLVS has a return on assets of -47.50%. Clovis Oncology, Inc. (NASDAQ:CLVS) quarterly performance is -43.69%.

Effective as of March 31, 2016, upon the previously announced resignation of Erle T. Mast as the Chief Financial Officer of Clovis Oncology, Inc. (NASDAQ:CLVS), Daniel W. Muehl, the Company’s current Vice President of Finance, has been appointed as the Company’s principal financial officer and principal accounting officer.

Synacor, Inc. (NASDAQ:SYNC) ended the last trading day at $1.38. Company weekly volatility is calculated as 6.56% and price to cash ratio as 2.64. Synacor, Inc. (NASDAQ:SYNC) showed a weekly performance of -3.50%.

On 16 March, Synacor, Inc. (NASDAQ:SYNC) reported total revenue was $32.4 million, an increase of 5% compared with $30.9 million in the fourth quarter of 2014. Search and advertising revenue was $19.3 million, a decrease of 22% compared with $24.9 million in the fourth quarter of 2014. Recurring and fee-based revenue was $13.1 million, an increase of 118% compared with $6.0 million in the fourth quarter of 2014.

On 01 April, International Paper Company (NYSE:IP) shares decreased -0.17% and was closed at $40.97. IP EPS growth in last 5 year was 7.00%. International Paper Company (NYSE:IP) year to date (YTD) performance is 10.07%.

International Paper (NYSE:IP) will release first-quarter 2016 earnings on Wednesday, April 27, 2016 before the opening of the New York Stock Exchange. The company will host a webcast to discuss earnings and current market conditions, beginning at 10 a.m. ET (9 a.m. CT).

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) shares increased 8.31% in last trading session and ended the day at $13.17. AERI has a return on assets of -42.20%. Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) quarterly performance is -46.13%.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) announced that on March 24, dosing commenced of the first patients enrolled in Mercury 2, the Company’s second Phase 3 registration trial of RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, a novel once-daily eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. RoclatanTM is a fixed dose combination of Aerie product candidate RhopressaTM (netarsudil ophthalmic solution) 0.02% and latanoprost, the most widely prescribed PGA (prostaglandin analogue).

Asta Funding Inc. (NASDAQ:ASFI) caters to the Services space. It has a net profit margin of 8.50% and weekly performance is 12.83%. On the last day of trading company shares ended up at $10.11.

On 31st March, Asta Funding, Inc. (NASDAQ:ASFI) announced that its Board of Directors, after careful consideration and in consultation with a special committee of the Board and its financial and legal advisors, has unanimously determined to recommend that shareholders reject MPF Investco 4, LLC’s, a direct, wholly-owned subsidiary of The Mangrove Partners Master Fund, Ltd. (“Mangrove”) unsolicited tender offer to acquire up to 3,000,000 shares of common stock of Asta at price of $9.00 per share (the “Mangrove Offer”). Furthermore, the Company has announced its intention to commence an issuer tender offer for 3,000,000 shares of Asta common stock pursuant to a “Dutch Auction” format at a price range of $9.50 to $10.25 per share.